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Objective: To determine the clinical features and presence in CSF of antineuronal antibodies in
patients with pathologically proven autoimmune encephalitis derived from a cohort of patients
with suspected Creutzfeldt-Jakob disease (CJD).
Methods: The Dutch Surveillance Centre for Prion Diseases performed 384 autopsies on patients
with suspected CJD over a 14-year period (1998–2011). Clinical information was collected from
treating physicians. Antineuronal antibodies were tested in CSF obtained postmortem by immu-
nohistochemistry on fresh frozen rat brain sections, by Luminex assay for the presence of well-
characterized onconeural antibodies, and by cell-based assays for antibodies against NMDAR,
GABABR1/2, GABAAR GLUR1/2, LGI1, Caspr2, and DPPX.
Results: In 203 patients, a diagnosis of definite CJD was made, while in 181 a variety of other
conditions were diagnosed, mainly neurodegenerative. In 22 of these 181, the neuropathologist
diagnosed autoimmune encephalitis. One patient was excluded because of lack of clinical infor-
mation. Inflammatory infiltrates were predominantly perivascular and consisted mainly of T cells.
The predominant locations were basal ganglia and thalamus (90%) and temporal lobes and hippo-
campus (81%). In 6 patients (29%), antineuronal antibodies were detected in postmortem CSF,
directed against Hu, NMDAR, GABABR1/2, Caspr2, and an unidentified synaptic antigen in 2.
The most frequent symptoms were dementia (90%), gait disturbance (86%), cerebellar signs
(67%), and neuropsychiatric symptoms (67%). Immunopathologic and clinical findings did not dif-
fer between autoantibody-negative patients and patients with antineuronal antibodies.
Conclusions: It is important to consider immune-mediated disorders in the differential diagnosis of
rapidly progressive neurologic deficits. Neurol Neuroimmunol Neuroinflamm 2015;2:e178; doi:
10.1212/NXI.0000000000000178
GLOSSARY
CJD 5 Creutzfeldt-Jakob disease; DSCPD 5 Dutch Surveillance Centre for Prion Diseases; DWI 5 diffusion-weighted
imaging; IVIg 5 IV immunoglobulin; NSA-Abs 5 antibodies directed against neuronal surface antigens; sCJD 5 sporadic
Creutzfeldt-Jakob disease.
Autoimmune encephalitis and sporadic Creutzfeldt-Jakob disease (sCJD) may present with sim-
ilar clinical, radiologic, electrophysiologic, and laboratory findings.1–4 In sCJD, the course of
disease is fatal, while autoimmune encephalitis associated with antibodies directed against neu-
ronal surface antigens (NSA-Abs) usually responds well to treatment.5,6
We encountered several patients with rapidly progressive dementia diagnosed as possible or
probable sCJD, who at autopsy at the Dutch Surveillance Centre for Prion Diseases (DSCPD)
turned out to have had potentially treatable autoimmune encephalitis. We retrospectively re-
viewed all prion-negative autopsy brain reports from the DSCPD to determine the number
of pathologically confirmed cases of autoimmune encephalitis in a cohort of patients with
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suspected sCJD. In addition, we determined
the clinical, radiologic, and neurophysiologic
characteristics of patients with pathologically
confirmed autoimmune encephalitis and
examined the CSF for the presence of anti-
neuronal autoantibodies.
METHODS Patients. The DSCPD performed 384 autopsies
on patients with suspected Creutzfeldt-Jakob disease (CJD) over a
14-year period (1998–2011).7 At brain autopsy, definite CJD was
diagnosed in 203 patients based on the presence of spongiosis and
positive prion staining. In 181 patients, neuropathology showed a
variety of other conditions, mainly neurodegenerative disorders
(table e-1 at Neurology.org/nn). In 22 patients, the pathologist
identified inflammatory infiltrates consistent with a diagnosis of
autoimmune encephalitis. Of these 22 patients, we collected
clinical information from treating physicians, including discharge
notes, laboratory, neurophysiology, and radiology results. One
patient lacked sufficient clinical information and was excluded
from the study.
Based on the clinical information, the 21 patients with path-
ologically proven autoimmune encephalitis were retrospectively
classified as probable, possible, or no CJD according to the
CDC Diagnostic Criteria for Creutzfeldt-Jakob Disease, 2010
(http://www.cdc.gov/ncidod/dvrd/cjd/resources/CDCs_Diagnostic_
Criteria_for_CJD-2010.pdf).
Standard protocol approvals, registrations, and patient
consents. Local ethical committee approval was obtained for
research on retained tissues after written informed consent was
given by the patients during life or their next of kin after death
(Medical Ethics Committee of the University Medical Centre
Utrecht 11-531/C). All information was analyzed anonymously.
Antineuronal antibody testing. Postmortem derived CSF
samples from all cases were stored at 280°C until testing. As
sampling was done postmortem, no serum samples were available
at the DSCPD. All CSF samples were tested for autoimmune
encephalitis–associated antineuronal antibodies in several assays
at a dilution of 1:2. CSF samples were tested on fresh frozen rat
brain sections for autoantibodies against neuronal cell surface
antigens, as previously described.8 Antibodies against the onco-
neural antigens HuD, CDR62 (Yo), Tr (DNER), amphiphysin,
CRMP-5 (CV2), NOVA-1 (Ri), Ma1/2, and Zic4 were assayed,
using another immunohistochemistry protocol9 combined with a
recently described multiplex bead-based assay.10 In addition, CSF
samples were tested on cultured hippocampal neurons and on
HeLa cells overexpressing NMDAR1, GABABR1/2, GABAAR,
GLUR1/2, and DPPX as previously described.9,11 Finally,
samples were tested in a commercial assay (EUROIMMUN,
Lübeck, Germany) for anti-LGI1 and anti-Caspr2 antibodies
(previously tested as voltage-gated potassium channel complex
antibodies). The sensitive assays on frozen rat brain sections
and cultured hippocampal neurons detect clinically relevant
(high serum titer) GAD65 and LGI1 antibodies in CSF,
rendering underreporting of antibodies by the lack of serum
availability unlikely.12
Neuropathology. Brains were removed at autopsy and selected
tissue samples were immediately frozen and stored at 280°C
while the rest of the brain was fixed in formalin and used for
histologic and immunologic purposes. Histopathologic examina-
tion was performed as described before.7,13 In short, relevant
sections were stained for a-synuclein, ubiquitin, amyloid-b,
and tau in all patients. In a subset of patients, additional immune
stainings were carried out for B cells (CD20), T cells (CD3, CD4,
and CD8), and macrophages (CD68).
RESULTS Pathology consistent with autoimmune
encephalitis was found at autopsy in 22 out of 384
(6%) patients with clinically suspected CJD, consti-
tuting 12% (22/181) of the patients who turned
out at autopsy not to have had CJD. Because one
patient lacked sufficient clinical information, we pre-
sent the clinical, pathologic, and serologic findings in
21 patients with pathologically confirmed autoim-
mune encephalitis. Detailed information on the pa-
tients is summarized in tables e-2 and e-3.
Neuropathology. In all 21 patients, inflammatory infil-
trates were present (figure e-1). Gliosis was observed
in 10 (48%) patients while vasculitis was seen in
none. The infiltrates were predominantly perivascular
in 15 (71%), predominantly parenchymal in 5
(24%), and both perivascular and parenchymal in
1 (5%) patient. The infiltrates consisted of CD3-
positive T cells in 14/15 (93%) patients tested.
CD8-positive cells were observed in 7/8 (88%) and
CD4-positive cells in 4/5 (80%) patients examined.
In 8/12 (67%) patients, CD20-positive B cells were
present, mainly in the perivascular infiltrates. CD68-
positive cells were seen in 11/13 (85%) patients.
Infiltrates were mainly located in the basal ganglia
and thalamus in 19 (90%), temporal lobes and hippo-
campus in 17 (81%), cerebellum in 12 (57%), frontal
lobes in 11 (52%), other cortical areas in 12 (57%),
brainstem in 7 (33%), and periventricular white mat-
ter in 4 (19%). Neuropathologic changes were far
more extensive than MRI changes.
Postmortem CSF testing for antineuronal antibodies.
Antineuronal antibodies were detected in 6/21
(29%) of the postmortem collected CSF samples.
Five of these antibodies were directed against NSA.
One each was directed against GABAB1/B2, NMDAR,
and Caspr2, while 2 CSF samples harbored antibodies
against an unidentified synaptic antigen (figure 1).
One additional sample contained antibodies against
the intracellular onconeural Hu antigen. Of the 4
known antibodies detected in CSF, the Hu antibody
had been described long before the time of the patient’s
illness, while GABAB1/B2, NMDAR, and Caspr2
antibodies were first reported after the death of the
respective patients. Three of the 6 patients with anti-
neuronal antibodies presented with limbic encepha-
litis, 2 with encephalomyelitis, and 1 with Morvan
syndrome (associated with anti-Caspr2 antibodies).
Further clinical findings in the 6 patients with
pathologically confirmed autoimmune encephalitis
and antineuronal antibodies are summarized in
table 1 and supplementary information (1). The
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phenotypes associated with the known antibodies are
classical for these disorders.14 The localization and
cellular composition of the inflammatory infiltrates
found at autopsy did not differ between the antibody-
positive and antibody-negative patients (table e-4).
Summarizing, 5/21 (24%) patients with patholog-
ically confirmed autoimmune encephalitis had CSF
autoantibodies directed against NSA (3 against well-
defined and 2 against unknown antigens).
Clinical characteristics. All 21 patients with autoim-
mune encephalitis had a rapidly progressive illness
with a median duration of 3.3 months and died
within 13 months of first symptoms (table 2, tables
e-2 and e-3). In retrospect, 14 of the 21 (67%) pa-
tients with autoimmune encephalitis fulfilled the clin-
ical 2010 CDC criteria for possible or probable sCJD
while 7 (33%) did not. In the subgroup of 6 patients
with antineuronal antibody–associated autoimmune
encephalitis, 67% (4 patients) also fulfilled CDC cri-
teria for possible or probable sCJD (table 2). The
most frequent main symptoms included dementia
(90%), cerebellar signs (67%), myoclonus (48%),
and extrapyramidal signs (33%) (table 3). Other
symptoms that were frequently present included gait
disturbance (86%), neuropsychiatric symptoms
(67%), and frontal lobe symptoms (62%). There
were no clear differences in clinical presentation of
autoimmune encephalitis with or without detectable
antineuronal antibodies in CSF (tables 2 and 3). Only
4 patients received immunotherapy, consisting of ste-
roids in 2, IV immunoglobulins (IVIg) in 1, and both
IVIg and steroids in 1. None of the patients showed
substantial improvement and immunotherapy was
discontinued in all 4.
Additional investigations. The CSF had been examined
in 18 of the 21 patients and was abnormal in 14/18
(78%), showing increased protein in 14 (78%), plei-
ocytosis in 10 (56%), and positive 14-3-3 protein in 9
(50%) (table 4).
EEG was performed at least once in 19 of the pa-
tients and was abnormal in 18/19 (95%) with an
increase of slow wave activities in 15/19 (79%). Seven
of the patients showed triphasic periodic complexes
that were considered compatible with CJD in 6
(32%). Epileptiform abnormalities were registered
in 7 (37%) of the patients (table 4).
MRI was abnormal in 10/17 (59%) patients,
showing increased signal on T2-weighted or fluid-
Figure 1 Unidentified synaptic antigen in CSF of 2 patients with autoimmune encephalitis
In 2 patients, a synaptic staining pattern in the hippocampus was observed not corresponding to any of the known antigens
tested. One patient was a 73-year-old man with limbic encephalitis (A, B; patient 11) and the other a 77-year-old man with
encephalomyelitis (C, D; patient 18). Immunohistochemistry was performed as described in the Methods (A, C). To confirm
the synaptic staining pattern in these 2 patients, CSF samples were incubated (1:2 dilution) live with primary hippocampal
cultures (B, D) as previously described.9
Neurology: Neuroimmunology & Neuroinflammation 3
ª 2015 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
attenuated inversion recovery images (table 4). Imag-
ing abnormalities were located in the medial temporal
lobes in 3, periventricular in 5 (most likely vascular
lesions in 3), basal ganglia and thalamus in 2, and
brainstem in 1. None of the patients had MRI
changes typical of sCJD, according to 2010 CDC
criteria, although most investigations lacked diffusion-
weighted imaging (DWI) sequences.
The patients with autoimmune encephalitis with
antineuronal autoantibodies in their CSF did not
clearly differ from the antibody-negative patients in
CSF, EEG, or MRI findings (table 4).
Associated tumors. In 9 patients (43%), a tumor was
present. Based on criteria published by an EU consor-
tium, the etiology of the neurologic syndrome could
be classified as definitely paraneoplastic in 5 and pos-
sibly paraneoplastic in 2.15 The tumor was probably
unrelated in 2 of the patients, precluding a paraneo-
plastic etiology. Detailed clinical and oncologic find-
ings are presented in table e-3 and supplementary
information (2).
DISCUSSION The first finding of our study is that
approximately 7% of patients with suspected CJD
Table 1 Clinical summary of 6 patients with pathologically confirmed autoimmune encephalitis and associated antineuronal autoantibodies
Characteristic antibody
Antigen specificity
Hu GABAB1/2 NMDAR Caspr2 Synaptic Synaptic
Sex/age at onset, y M/74 F/70 F/49 M/55 M/77 M/73
CJDa Possible No Possible Possible Probable No
Onset Subacute Subacute Subacute Subacute Subacute Subacute













Classical syndrome EM LE LE Morvan syndrome EM LE
Cognitive decline Yes Yes Yes Yes Yes Yes
Myoclonus Yes No Yes No Yes Yes
Cerebellar signs Yes No No Yes Yes No
Pyramidal signs Yes No No No Yes No
Akinetic mutism No Yes No No No No
Neuropsychiatric No Yes Yes Yes Yes Yes
Disorder of frontal brain No Yes Yes Yes Yes Yes
Gait disturbance Yes Yes Yes Yes Yes No
Epilepsy Yes Yes Yes Yes No Yes
Aphasia No Yes No No Yes No
Autonomic dysfunction Yes No No No No No
Central hypoventilation No No No No No No
CSF cell count Unknown 14 WBC 47 WBC Unknown 18 WBC 8 WBC
CSF 14-3-3 Positive Not tested Negative Negative Negative Positive

















Cancer SCLC No No No No No
Treatment No No MP, P, IVIg,
ovariectomy
No No No
Improvement (mRS) No No No No No No
Disease duration, mo 2.6 1.5 12.3 3.3 1.3 4.7
Abbreviations: CJD 5 Creutzfeldt-Jakob disease; EM 5 encephalomyelitis; FLAIR 5 fluid-attenuated inversion recovery; IVIg 5 IV immunoglobulin; LE 5
limbic encephalitis; MP 5 methylprednisolone; mRS 5 modified Rankin Scale; P 5 prednisone; SCLC 5 small-cell lung cancer; WBC 5 white blood cells.
a Retrospective classification based on clinical information (before autopsy), according to CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease, 2010
(see Methods).
bGeneralized atrophy, periventricular leukoaraiosis, and multiple lacunar lesions.
c Aspecific probably vascular white matter lesions and mild hippocampus atrophy (Scheltens grade II).
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have autoimmune encephalitis at autopsy. Secondly,
antineuronal autoantibodies could be demonstrated
in the CSF from 6 of 21 (29%) patients with patho-
logically confirmed autoimmune encephalitis. One
case each of anti-Hu, GABAB1/B2, NMDAR, and
Caspr2 was detected, while 2 CSF samples had
antibodies against an unidentified NSA. Third, in
retrospect, 67% of the patients met the 2010 CDC
criteria for possible or probable CJD, both in the
antibody-positive and antibody-negative group.
Several other studies have addressed the clinical
overlap between prion disorders and autoimmune
encephalitis. Chitravas et al.3 studied prion-negative
brain autopsy cases referred to the US National Prion
Disease Pathology Surveillance Center. Neuropathol-
ogy diagnosed an immune-mediated disorder in 26/
304 (8.5%) of the prion-negative cases with histol-
ogy, including primary angiitis of the CNS (7), acute
disseminated encephalomyelitis (6), limbic encepha-
litis (6), neurosarcoidosis (4), paraneoplastic cerebel-
lar degeneration (2), and granulomatosis with
polyangiitis (Wegener) (1). This study did not report
the antineuronal antibody status of the patients. In
contrast to our study, most of the misdiagnosed pa-
tients did not meet the WHO criteria for CJD.
Grau-Rivera et al.1 examined the presence of NSA-
Abs in the CSF of patients with suspected or patho-
logically confirmed CJD. NSA-Abs were found in 6
of 346 patients (1.7%) with a rapidly progressive neu-
rologic disorder suggestive of CJD during life. In con-
trast to our study, none of these 6 patients met the
diagnostic criteria for probable or possible CJD. The
target antigens included NMDAR, LGI1, Caspr2,
aquaporin 4, Tr (DNER), and an unknown protein.
All patients stabilized or improved after appropriate
treatment. None of the 49 patients with definite CJD
had NSA-abs. Another study reported serum NSA-
Abs in ,5% of patients with sCJD, all at very low
titers.2 In this study, we tested CSF of all patients
identified with autoimmune encephalitis at autopsy.
CSF is proven more sensitive and specific to detect
NSA-Abs as shown for NMDR,16 AMPAR,17 and
GABABR.18
In 50% of our patients with autoimmune enceph-
alitis tested, 14-3-3 protein was elevated in CSF (part
of the CDC’s 2010 diagnostic criteria), casting fur-
ther doubt on the usefulness of this test in diagnosing
CJD.19 EEG was also not useful as triphasic waves
were present in 32% of our autoimmune patients.
None of our patients with autoimmune encephalitis
showed sCJD-specific MRI abnormalities, support-
ing the higher specificity of sCJD MRI criteria over
14-3-3.19,20 However, DWI was not performed in
most of our patients, and we do not know whether
DWI would have retained its specificity in this series.
On the other hand, 56% of patients had an increased
leukocyte count (.5 3 10E9/L) in their CSF.
Although the pleiocytosis was usually mild, it pro-
vides a clue to an inflammatory etiology.
Other studies describing clinical overlap between
prion and autoimmune disorders focused primarily
on rapidly progressive dementia, detecting a 2%–
9% prevalence of immune-mediated disorders.21–23
In a series of patients with suspected autoimmune
Table 2 Clinical characteristics in 21 patients with autoimmune encephalitis
and suspected CJD
Characteristic All (n 5 21)
CSF antibody
positive (n 5 6)
No CSF antibody
(n 5 15)
Male/female 15/6 4/2 11/4
Median (range) age at onset, y 72 (37–82) 70 (50–77) 72 (37–82)
Mean age at onset, y 68 67 69
Median (range) disease duration, mo 3.3 (1.0–12.3) 4.4 (1.3–12.3) 3.3 (1.0–11.5)
Mean disease duration, mo 4.2 4.4 4.2
Diagnosis according to CDC criteria
(2010) for sCJD, n (%)
Probable 8 (38) 1 (17) 7 (47)
Possible 6 (29) 3 (50) 3 (20)
No 7 (33) 2 (33) 5 (33)
Abbreviations: CJD 5 Creutzfeldt-Jakob disease; sCJD 5 sporadic Creutzfeldt-Jakob
disease.
Table 3 Symptoms in 21 patients with autoimmune encephalitis and suspected
CJD
All CSF antibody positive No CSF antibody
Main symptoms, n (%)
Dementia 19 (90) 6 (100) 13 (87)
Cerebellar signs 14 (67) 3 (50) 11 (73)
Myoclonus 10 (48) 4 (67) 6 (40)
Extrapyramidal signs 7 (33) 2 (33) 4 (27)
Akinetic mutism 5 (24) 1 (17) 4 (27)
Pyramidal signs 5 (24) 1 (17) 4 (27)
Visual symptoms 2 (10) 1 (17) 1 (7)
Other symptoms, n (%)
Gait disturbance 18 (86) 5 (83) 13 (87)
Neuropsychiatric 14 (67) 5 (83) 9 (60)
Apathy/social withdrawal 8 (38) 2 (33) 6 (40)
Agitation/anxiety 9 (43) 4 (67) 5 (33)
Hallucinations 5 (24) 3 (50) 2 (13)
Disorder of frontal braina 13 (62) 5 (83) 8 (53)
Epilepsy 7 (33) 5 (83) 2 (13)
Aphasia 6 (29) 2 (33) 4 (27)
Autonomic dysfunction 4 (19) 1 (17) 3 (20)
Central hypoventilation 2 (10) 0 2 (13)
Abbreviation: CJD 5 Creutzfeldt-Jakob disease.
a Including bradyphrenia, perseveration, utilization, echolalia, and disinhibition.
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dementia and good response to immunotherapy,
almost 9% of the disorders had initially been diag-
nosed as sCJD.24 In particular, patients with enceph-
alitis associated with LGI1-Abs may present with
myoclonus-like movements and other symptoms that
can be mistaken for CJD.4
In general, the prognosis of autoimmune enceph-
alitis appears to be determined by the involved immu-
nopathogenic mechanisms.25 Disorders accompanied
by antibodies directed against intracellular antigens
are probably T-cell-mediated and generally respond
poorly to immunotherapy. Most paraneoplastic
neurologic disorders with onconeural antibodies
belong to this category. On the other hand, in disor-
ders associated with NSA-Abs, the antibodies are
probably pathogenic and these disorders respond
favorably to first- and second-line immunotherapy.
Examples include NMDAR,5 LGI1,26,27 and
Caspr227,28 encephalitis. The immunopathology of
NSA-Abs-associated encephalitis shows mild to mod-
erate, mainly perivascular, lymphocytic infiltrations
containing both B and T cells, antibody-producing
cells, and immunoglobulin G deposits.29–31 It is pos-
sible that we missed some cases with burned out or
with bland neuropathology and that the 22 cases that
we identified represent an underestimation. The
encephalitis associated with Hu or Ma2 antibodies
is characterized by extensive B and T cell lymphocytic
infiltrations, containing T cells with a cytotoxic phe-
notype.31–33 In our series, immunopathologic findings
did not differ between autoantibody-negative patients
and the patients with NSA-Ab (table e-4), nor did
clinical, CSF, radiologic, or electrophysiologic char-
acteristics (tables 2–4). The immunopathologic
mechanism in the 15 patients with autoimmune
encephalitis without detectable autoantibodies re-
mains unclear. It cannot be excluded that some of
these patients harbored NSA-Abs that were degraded
by postmortem interval or during storage at 280°C
in low protein CSF. The lack of serum availability
may also have contributed to underreporting of
NSA-Abs.
Limitations based on the retrospective nature of
the study are applicable. In addition, bias was intro-
duced by the fact that all patients had suspected CJD
and had come to autopsy. In particular, the poor
outcome with a median survival of 3.3 months
(range 1.0–12.3 months) in this study of autoim-
mune encephalitis was largely determined by this
inclusion bias.
It is important to consider both prion and
immune-mediated disorders in the differential diag-
nosis of rapidly progressive neurologic deficits, know-
ing that EEG and 14-3-3 in CSF do not discriminate
sufficiently to distinguish the two. Detection in
serum or CSF of specific antineuronal antibodies
can establish a diagnosis of autoimmune encephalitis
and guide appropriate treatment.
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CSF sampled, n 18/21 6/6 12/15
Protein or cell count, n (%)
Abnormal 14 (78) 4 (67) 10 (83)
Normal 2 (11) 0 2 (17)
Not known 2 (11) 2 (33) 0
White cell count, n (%)
Median (range) 310E9/L 12 (0–47) 16 (8–47) 11 (0–33)
Increased (>5 3 10E9/L) 10 (56) 4 (67) 6 (50)
Normal 4 (22) 0 4 (33)
Not known 4 (22) 2 (33) 2 (17)
14-3-3 protein, n (%)
Positive 9 (50) 2 (33) 7 (58)
Negative 5 (28) 3 (50) 2 (17)
Not tested 4 (22) 1 (17) 3 (25)
EEG performed, n 19/21 6/6 13/15
EEG overall abnormal, n (%) 18 (95) 5 (83) 13 (100)
Increase in slow wave activities 15 (79) 4 (67) 11 (85)
Triphasic periodic complexes 7 (37) 3 (50) 4 (31)
Complexes compatible with CJD 6 (32) 2 (33) 4 (31)
MRI performed, n 17/21 6/6 11/15
MRI overall, n (%)
Abnormal 10 (59) 4 (67) 6 (55)
Normal 7 (41) 2 (33) 5 (45)
T2/FLAIR increased signal, n (%)
Yes 10 (59) 4 (67) 6 (55)
No 7 (41) 2 (33) 5 (45)
Gadolinium enhancement, n (%)
Yes 0
No 17 (100)
Abbreviations: CJD 5 Creutzfeldt-Jakob disease; FLAIR 5 fluid-attenuated inversion
recovery.
Areas with increased T2/FLAIR signal included periventricular white matter (5), mesiotem-
poral lobe and hippocampus (3), brainstem (3), basal ganglia and thalamus (2), cortex (2), and
internal capsule (1). Generalized atrophy was present in 5 patients, bifrontal atrophy in 2,
and hippocampal atrophy in 1.
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